Valuation: Verde Science, Inc.

Market Cap 148K 129K 119K 110K 207K 14.13M 211K 1.41M 553K 7.02M 556K 544K 23.6M P/E 2013
-9.91x
P/E 2014 -0.23x
Enterprise Value 407K 353K 328K 303K 570K 38.84M 580K 3.89M 1.52M 19.29M 1.53M 1.49M 64.87M EV / Sales 2013
-
EV / Sales 2014 -
Free-Float
90.01%
Yield 2013 *
-
Yield 2014 -
Manager TitleAgeSince
Chief Executive Officer 61 2012-06-13
Director TitleAgeSince
Chairman 61 2012-06-13
Director/Board Member 63 2014-03-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-48.84% - - 23
-0.81%-0.33%+27.15%+81.12% 55.23B
-3.74%-6.32%+42.70%+64.45% 53.75B
-0.11%+0.86%-15.63%-13.56% 23.48B
-1.58%-5.51%-3.51%+375.36% 22B
+2.65%-0.72%+20.56%-11.97% 19.78B
-1.23%-3.15%+26.00%-31.88% 17.44B
+2.12%-4.71%+17.74%+548.31% 14.66B
+1.16%+0.58%+51.87%+181.96% 14.07B
-5.09%-10.87%+153.11%+272.20% 13.02B
Average -0.69%-1.55%+35.55%+162.89% 25.94B
Weighted average by Cap. -1.18%-0.44%+30.82%+125.23%

Financials

2013 2014
Net sales - -
Net income -798K -693K -644K -594K -1.12M -76.2M -1.14M -7.62M -2.98M -37.84M -3M -2.93M -127M -2.61M -2.27M -2.11M -1.94M -3.66M -249M -3.73M -24.95M -9.77M -124M -9.81M -9.6M -417M
Net Debt 252K 219K 203K 187K 353K 24.02M 359K 2.4M 941K 11.93M 945K 924K 40.12M 259K 225K 209K 193K 363K 24.71M 369K 2.47M 968K 12.27M 972K 951K 41.28M
Logo Verde Science, Inc.
Verde Science, Inc. is a pharmaceutical research and development company. The Company is engaged in medical science consulting business. The Company is focused on the discovery of drugs and treatment modalities, as well as diagnostic devices and pharmaceutical delivery systems for the treatment of diseases and medical issues. The Company is focused on developing medicinal formulations from cannabinoids and tetrahydrocannabinol (THC) compounds for the treatment of various issues, such as migraines, glaucoma, loss of appetite from cancer therapies, and other medical issues. The Company is focused on launching its THC Pharmaceutical Development Program by executing a research program, which involves developing formulations preparing protocols for clinical trials.
Employees
-